A rapid, sensitive, and specific radioimmunoassay has been developed for the measurement of amikacin, a new semisynthetic aminoglycoside antibiotic. Antisera were produced by immunizing rabbits with amikacin conjugated to porcine thyroglobulin. Sera were screened for amikacin antibodies with 3H-labeled amikacin. Free and bound radioactivity were separated by the second antibody method. As little as 5 ng of the antibiotic can be measured in serum, cerebrospinal fluid, and urine. The standard curve is unaffected by pH (5-11), ionic strength (0.01 M to 0.3 M), MgCl2 or CaCl2 (1 to 8 mM/liter), or urea (10-300 mg/100 ml). The antibodies raised to amikacin are not able to distinguish between kanamycin and amikacin. The cross reactivity of all other antibiotics tested was <0.1%. Co-incubation of first and second antibody allows for a 30-min incubation period, making the assay useful for stat determinations. The standard curve is linear on a logit-log plot, allowing for rapid computer analysis of the standard curve, interpolation of sample values, and quality-control monitoring.
Radioimmunoassay is a precise, sensitive, and specific analytical technique which has recently become available for the detection and measurement of drugs in biological fluids (5, 6, (10) (11) (12) (13) .
Amikacin (BB-K8) is a new semisynthetic aminoglycoside antibiotic with a broad spectrum of in vitro and in vivo antibacterial activity (4, 7) . Like other aminoglycosides, amikacin at high doses is potentially ototoxic and nephrotoxic (2) . To achieve and maintain therapeutic levels, particularly in individuals with impaired renal function, frequent and rapid monitoring of blood levels is paramount to make valid decisions concerning the dose and dosing intervals.
The present paper reports the development of a rapid radioimmunoassay for amikacin. The assay can be performed in 2 Aliters of 'H-labeled amikacin containing approximately 10,000 counts/min of 'H. The tubes were vortexed and incubated at 4 C for 24 h. To separate free from bound radioactivity, 100 guliters of sheep anti-rabbit gamma globulin (previously titered to determine the volume needed for maximum precipitation of first antibody) was added to all tubes and vortexed. The tubes were incubated at 4 C for an additional 24 h and then centrifuged. The bound radioactivity was counted in the precipitate after aspiration. An antiserum which bound 32% of the radioactivity at a final dilution of 1:100 was used in the assay.
Radioimmunoassay. The assay was run in serological test tubes (10 by 75 mm) with 50-Aliter, 100-uliter Eppendorf, and 1-ml Oxford automatic pipettors (Scientific Products, Santa Ana, Calif.). For an 11-point standard curve, with high, middle, and low controls, and unknown samples, all in triplicate, the protocol used was as follows. A stock solution of amikacin was prepared by dissolving 10 mg in 100 ml of 1% NRS in PBS. Three working standard solutions were prepared by diluting the stock solution 1:10, 1:100, and 1:1,000 in 1% NRS in PBS. Amounts from 20 to 100 Mliters of the appropriate working solution were used to give standard curve points of 1, 2, 4, 6, 8, 10, 25, 50, 100, 250, and 1000 ng (Fig. 1) Radioactivity was counted in a Beckman LS-333 beta liquid scintillation counter with an efficiency of 43% for tritium. The counter was set to record time to 10,000 counts (2% error).
RESULTS AND DISCUSSION
All five rabbits immunized with the amikacin conjugate produced antibodies at first bleeding. The binding of labeled amikacin ranged from 21 to 56% at a 1:10 initial of the rabbit serum or a 1:100 final solution in the assay system with the labeled amikacin as received without further purification. The standard curve obtained with one of the antisera is shown in Fig. 1 .
Two standard deviations below the mean of the counts precipitated in the absence of unlabeled amikacin was used to determine assay susceptibility. Assay susceptibility was 5 ng/ tube.
When serum, urine, and cerebrospinal fluid were enriched with increasing amounts of a stock solution of amikacin in PBS, the displacement curves paralleled the standard curve and the recovery curves were linear with a slope of 1 Maximum binding of labeled amikacin was reached with a first antibody incubation of 10 min at 4 C. Binding was unaffected when first antibody and second antibody were incubated simultaneously. Co-incubation of first antibody with second antibody for 10 min at 40 C followed by 20 min at 4 C achieved maximum binding of labeled amikacin. The total incubation time of 30 min enhances the utilization of this radioimmunoassay for stat determinations of amikacin (1) .
The rapidity of microbiological assays may be nullified by the presence of certain antibiotics. To test the specificity of the antibody for amikacin, cross-reactivity studies were conducted. The results were expressed as the relative potency of other drugs compared to amikacin, for the 50% displacement of labeled amikacin. The percentage of cross-reactivity was less than 0.1% for all antibiotics tested except kanamycin ( Table 1 ). The antibodies raised to amikacin were not able to distinguish the difference between kanamycin and amikacin which is derived from the acylation of the deoxystreptamine moiety of kanamycin A (4). Further specificity studies showed cross-reactivities of less than 0.1% with a wide variety of other drugs listed as follows: chlorthiazide, metaraminol, cyclophosphoramide, mephentermine, hydrocortisone, digoxin, imuran, chlordiazepoxide, sodium iodide, aminophyllin, pentazocine lactate, levanterenol bitartarate, sodium pheno- 
